April 4 (Reuters) - Amarin Corporation PLC:
* IT CARDIOVASCULAR OUTCOMES STUDY REACHES 100% MARK FOR ESTIMATED ONSET OF TARGET PRIMARY MAJOR ADVERSE CARDIOVASCULAR EVENTS
* MAINTAINS ITS GUIDANCE TO REPORT TOP-LINE RESULTS FROM STUDY BEFORE END OF Q3 2018. Source text for Eikon: Further company coverage: